An evaluation of a Mosquito home system for controlling *Aedes aegypti*

Ahmad Mohiddin Mohd Ngesom¹, Anis Ahmad Razi¹, Nur Syahirah Azizan¹, Nazni Wasi Ahmad², Asmalia Md Lasim³, Yanfeng Liang⁴, David Greenhalgh⁴, Jasmine Chia Siew Min⁵, Mazrura Sahani¹, Rozita Hod⁶ and Hidayatulfathi Othman¹*

¹ Center for Toxicology and Health Risk, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Federal Territory of Kuala Lumpur.

² Medical Entomology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia.

³ Phytochemistry Unit, Herbal Medicine Research Centre (HMRC), Institute for Medical Research, National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia.

⁴ Department of Mathematics and Statistics, University of Strathclyde, Glasgow G1 1XH, UK.

⁵ Department of Biomedical Science, Faculty of Medicine and Health Science, Universiti Putra Malaysia, 43400 Serdang, Selangor.

⁶ Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, 50600 Cheras, Kuala Lumpur.

*Corresponding Author: hida@ukm.edu.my

E-mails:
AMMN: aksmohiddin@yahoo.com
AAR: anisrazi123@gmail.com
NSA: syerazizan@gmail.com
An evaluation of a Mosquito home system for controlling Aedes aegypti

NWA: nazni@imr.gov.my
AML: asmaliaceb@gmail.com
YL: yanzfeng.liang@hotmail.com
DG: david.greenhalgh@strath.ac.uk
JCSM: jasminechiasiewmin@gmail.com
MS: mazr@ukm.edu.my
RH: rozita.hod@ppukm.ukm.edu.my
HO: hida@ukm.edu.my
Abstract

Background: Dengue is a significant public health issue that is caused by *Aedes* spp. mosquitoes. The current vector control methods are unable to effectively reduce *Aedes* populations and thus failing to decrease dengue transmission. Hence, there is an urgent need for new tools and strategies to reduce dengue transmission in a wide range of settings. In this study, the Mosquito home system (MHS) and Mosquito home aqua (MHAQ) formulations were assessed as commercial autodissemination traps in the laboratory and small-scale field trials.

Method: Multiple series of laboratory and small-scale field trials were performed to assess the efficacy of MHS and MHAQ exposed to *Ae. aegypti*. In the laboratory trials, various parameters such as fecundity, fertility, wing size, oviposition preferences, residual effects, and MHAQ transference to other containers through controlled experiments were tested. For small-scale field trials, the efficacy of the MHS and MHAQ approaches was determined to ascertain whether wild mosquitoes could transfer the MHAQ formulation from MHS stations to ovitraps.

Results: The data revealed that *Ae. aegypti* was highly susceptible to low concentrations of MHAQ formulations and had a residual effect of up to three months, with MHAQ exposure affecting fecundity, fertility, and mosquito wing size. In the oviposition studies, gravid females strongly preferred the hay infusion compared to tap water and MHAQ during egg-laying in the laboratory. Nevertheless, the use of commercial MHAQ by MHS was highly attractive in field settings compared to conventional ovitraps among local *Aedes* spp. mosquitoes. In addition, MHAQ horizontal transfer activities in the laboratory and small-scale field trials were demonstrated through larval bioassays. These findings demonstrated the potential of MHAQ to be transferred to new containers in each study site.

Conclusion: This study provided proof of principle for the autodissemination of MHAQ. Through further refinement, this technique and device could become an effective oviposition trap and offer an alternative preventive tool for vector control management.
**Keywords:** Autodissemination, horizontal transfer, inhibition emergences, insect growth regulators, vector control management.

**Background**

*Aedes aegypti* and *Aedes albopictus* are both primary dengue vectors that are found in Malaysia [1], which ranks third in the number of dengue cases reported amongst countries in the Western Pacific Region [2]. Dengue can be transmitted through the bites of female *Aedes* spp. mosquitoes, with *Ae. aegypti* and *Ae. albopictus* most efficiently adapted to human dwelling areas with artificial container habitats that have a large amount of food.

Although the first licensed dengue vaccine named Dengvaxia was developed against all dengue serotypes [3], the implementation of Dengvaxia was limited to subnational public health programs in Brazil and the Philippines [4]. It offers limited efficacy and can increase the severity of dengue, especially against serotypes 1 and 2 [5-6]. Therefore, the best prevention strategy is to control the populations of *Aedes* mosquitoes and minimize the presence of mosquitoes [7-8].

The control measures against *Aedes* spp. populations are based on the recommendations of the World Health Organization (WHO), including implementing source reduction strategies, larvicides, biological controls, lethal oviposition trap, and insecticides that are used intensively during dengue outbreaks. In Malaysia, thermal fogging and ultra-low volume sprays are the primary interventions when dengue cases are reported [9]. However, uncontrolled use of insecticides during epidemics resulted in increased resistance among mosquitoes to major pesticide classes such as pyrethroids, organophosphates, and carbamate classes [10-13].

Pyriproxyfen is a broad-spectrum insect growth regulator that inhibits the emergence of mosquitoes [14] and is categorized as an eco-friendly pesticide, whereby its application does not remain in water and soil, and its biological degradation cycle serves as a carbon source for other microorganisms.
In addition, pyriproxyfen has also been approved for use in drinking water at the recommended application rate [17]. Pyriproxyfen possesses an unexploited potential as a larvicide against mosquitoes, with the autodissemination of pyriproxyfen being suggested by researchers as a novel form of vector control [19-21].

Autodissemination is a very promising and attractive concept that exploits the behavior of female mosquitoes to transfer small particles of insecticides to other cryptic sites [22] and thus prevents the emergence of immature larvae [23]. This was initially demonstrated in the laboratory [24] and subsequently validated by other researchers [25]. Recently, Abad-Franch et al. discovered that mosquitoes could efficiently transfer pyriproxyfen to artificial sites with 100% coverage of dwelling sites within 50 ha which generated more than a ten-fold increase in pupal mortality and, as a result, leading to a decrease in adult emergence [18]. Studies using autodissemination techniques conducted in Manacapuru, a city in Brazil with 60,000 inhabitants, have shown a reduction in the *Ae. aegypti* and *Culex* spp. populations [26]. Further research demonstrated that female mosquitoes could be contaminated, leading to the transfer of pyriproxyfen to other oviposition sites and significantly inhibited adult emergence in laboratory settings and under field conditions [19].

The Mosquito home system (MHS) is the first commercial trap in Malaysia to adopt the autodissemination concept using the Mosquito home aqua (MHAQ) solution. The trap is made of low-cost polyethylene and operates without electricity or any additional extensions. Its design is based on a gravity-fed watering system that effectively dispenses a trap solution for up to two months. Female mosquitoes are exposed to the solution inside the traps by tarsal contact during oviposition, and the insecticide is transferred to other oviposition sites. Over the years, several studies have been performed on MHS and MHAQ and have yielded promising results, although they have been poorly documented [27]. Thus, this study aimed to investigate the efficacy of autodissemination approaches against *Ae. aegypti* in laboratory settings using the MHS devices and MHAQ formulations. In small-scale field
evaluations, the efficacy of the MHS and MHAQ approaches were evaluated to ascertain whether wild mosquitoes were able to transfer the MHAQ formulation from MHS stations to the ovitraps. It was anticipated that MHS and MHAQ may have a significant impact on \textit{Ae. aegypti} and potentially emerge as a vector control tool.

**Methods**

**Mosquitoes**

A susceptible strain of \textit{Ae. aegypti} known as the Institute for Medical Research IMR strain which originated from Selangor was used in all experiments in this study and was free from any insecticide exposure. It was maintained in colonies for more than F1000 generations in the insectarium of IMR, Kuala Lumpur. The mosquitoes were reared in the Laboratory of Medical Entomology, Universiti Kebangsaan Malaysia at $26 \pm 4$ °C and $60 \pm 20\%$ relative humidity (RH). Larvae were fed TetraMin® fish food and cotton soaked with 10% sucrose was fed to adult mosquitoes as nourishment. Female mosquitoes obtained from the F0 generation fed on guinea pig (\textit{Cavia porcellus}) blood and their F1 and F2 progenies were used in the present study.

**Pyriproxyfen**

MHAQ is a commercial solution containing 0.004% pyriproxyfen and is used in conjunction with the MHS device (One Team Networks, Sdn. Bhd., Malaysia). The full information of the formulation cannot be disclosed as it is a trade secret of the company.

**Mosquito home system as autodissemination station**

The MHS trap (Fig. 1) is a cylinder-shaped black polyethylene container that is 19.7 cm in height and 14.6 cm wide. The MHAQ formulation attracts mosquitoes to enter and leave the trap through a row of holes
located at the top of the station. The inside of the trap has a black surface with a bottle screw adapter at the bottom. The MHAQ solution bottle can be easily screwed to the base which was convenient when the solution bottle needed replacement. The design utilized gravity flow to provide a continuous flow of the solution into the reservoir, with the flow ceasing once the reservoir is filled, ensuring the availability of the formulation for up to two months. Traps were lined with paper towels as an oviposition substrate for Aedes spp. mosquitoes and mosquitoes that were exposed to the solution became contaminated with MHAQ when they entered the trap to oviposit on the paper towel and remained contaminated when they exited to find other containers.

**Evaluation of dose-response to MHAQ**

Larval bioassays were performed using the standard WHO larval bioassay [28]. Eight different concentrations of MHAQ (0.02 ppm to 1.28 ppm) were used, resulting in a range of larval mortality from 0 to 100%. A total of a hundred *Ae. aegypti* 3rd instar larvae were exposed to each of the concentrations and fifty larvae were exposed to a control containing distilled water with no insecticide. Each cup containing a specific concentration of MHAQ was made by mixing 99 ml of distilled water and 1 ml of insecticide according to the desired concentration. The control treatment consisted of 99 ml of distilled water and 1 ml acetone and each concentration was replicated four times. Pupal mortality was recorded after an exposure of 24 h and the lethal concentration (LC$_{50/90}$) was calculated.

In order to obtain the emergence inhibition (EI), preliminary tests were conducted by exposing the test larvae to a wide range of concentrations. Based on these results, nine different concentrations (0.07 ppb – 0.70 ppb) of MHAQ were used, yielding between 5% and 95% in the range of EI. The bioassays were performed using twenty *Ae. aegypti* 3rd instar larvae for each concentration. The larvae were placed into a 250 ml paper cup containing 99 ml distilled water and 1 ml of insecticide, then placed inside a mosquito cage. The control treatment contained 99 ml distilled water and 1 ml acetone, and five replicates
were tested for each concentration. Due to the delayed action of pyriproxyfen, larval and pupal mortalities were assessed every day until all individuals had either emerged or died in the control group. Throughout the study, larvae were provided with TetraMin® fish food at 100 mg/liter until pupae emerged [29-30]. For each bioassay, the temperature was maintained at 26 ± 4 °C with 60 ± 20% RH and a 12-h light: 12-h dark photoperiod.

Transfer of MHAQ to untreated containers

In order to demonstrate the transfer of MHAQ to another container, a binary choice test were performed in a small mosquito cage (L: 30 × W: 30 × H: 30 cm) under laboratory conditions of 26 ± 2 °C and 60 ± 20% RH, based on the studies by Chism & Apperson [25] and Sihuincha et al. [31]. A binary choice test [25] was performed with each cage holding a batch of gravid females (1-2 weeks old, four days post-blood-feeding). Two ovitraps (250 ml capacity, 7.2 cm diameter, 9 cm height) were placed by simple randomization in diagonal corners of each cage. The treatment cage contained two ovitraps; one with an oviposition strip treated with MHAQ and the other with an untreated filter paper in tap water only. The control cage also contained two ovitraps, both lined with untreated filter paper and filled with 100 ml of tap water. The MHAQ was prepared as an emulsifiable form to be released effectively during oviposition of the mosquito [32]. Cotton balls soaked with 10 % sucrose were supplied in each cage.

Gravid female mosquitoes from the same batch were given a dual choice [25] between the particular concentration of MHAQ and tap water under the following conditions: (1) one gravid with 0.5 ppm, (2) one gravid with 10 ppm, (3) one gravid with 20 ppm, (4) one gravid with 40 ppm, (5) three gravid with 0.5 ppm, (6) three gravid with 10 ppm, (7) three gravid with 20 ppm, (8) three gravid with 40 ppm, (9) five gravid with 0.5 ppm, (10) five gravid with 10 ppm, (11) five gravid with 20 ppm, and (12) five gravid with 40 ppm of MHAQ. In order to ensure that ovitrap placement did not influence oviposition choice, the ovitrap was rotated clockwise over time in each replicate of each experiment. Each treatment
was replicated five times and the complete assays were repeated three times. The mosquitoes were left to lay eggs and all the samples and equipment were discarded after 72 h. Twenty larvae were introduced into water samples collected from ovitraps filled with tap water (treatment cage and control cage) and monitored daily until all the larvae and pupae in the control ovitraps had either died or emerged as adults. Successful MHAQ contamination and transferability were evaluated by comparing the differences in larvae/pupal mortality and EI of each ovitrap between treatment and control experiments.

**Oviposition preferences of *Aedes aegypti*** **to MHAQ in competition with water**

The oviposition site selection bioassay procedures have been slightly modified based on previous reports [33-34]. The attraction of *Ae. aegypti* to commercial MHAQ solutions in the presence of multiple oviposition sites was determined using a cage containing sixty females (3-5 days non-blood-fed) and fifteen males (2-5 days old), and blood meal was offered after 30 mins of combining. After three days blood-fed, fifteen females were randomly transferred to a new cage containing four oviposition cups filled with a Whatman® No. 1 filter paper (Merck Millipore, USA) and 200 ml of the following solutions: (i) MHAQ solution - MHAQ, (ii) Hay Infusion - HI, (iii) Tap Water a – TW a and, (iv) Tap Water b – TW b, respectively (Fig. 2a).

In a second experiment, the preference of female mosquitoes to oviposit in small water sources was determined by exposing fifteen females to the following solutions: (i) MHAQ, (ii) TW a, (iii) TW b, and (iv) TW c (Fig. 2b). In addition, the preference of mosquitoes to oviposit in various containers was also assessed in the third experiment using the MHAQ a, MHAQ b, MHAQ c, and TW a solutions (Fig. 2c). Every oviposition site containing MHAQ solution and tap water in each experiment was replicated four times and the position of the cup was randomized (Fig. 2). A new batch of fifteen females was used in each experimental replicate. In all of the three experiments, the mosquitoes were allowed to lay eggs
for three days on the Whatman® No. 1 filter paper, and their egg deposition assessed through examination of the filter paper.

**Residual larvicide activity of MHAQ**

In order to assess the residual larvicidal activity of MHAQ, four different concentrations (0.5 ppm, 1.0 ppm, 20 ppm, and 40 ppm) were evaluated in laboratory settings and covered with a net to prevent ovipositing of any mosquitoes. A total of five beakers (15 cm diameter x 18 cm height) were placed approximately 30 cm from each other, with four beakers were filled with 2.0 liters of different MHAQ solution concentrations and the remaining beaker with tap water as a control. These bioassays were performed in replicates of three for every concentration and control. Batches of 20 larvae were released on day-0, with the replacement of larvae carried out every ten days via the introduction of new larvae batches, and observation was conducted for 90 days. Every time larvae were replaced, all the larvae and pupae were counted, removed and the surviving larvae transferred into paper cups for further observations. Larvae were supplied with TetraMin® fish food and experiments were carried out at 26 ± 4 °C and 60 ± 20% RH with a 12: 12 day: night photoperiod.

**Effect of MHAQ on fecundity and fertility**

Colonies of *Ae. aegypti* were subjected to a sublethal dose LC$_{50}$ [35] (where 50% of the mosquitoes could still be alive and capable of producing first-generation progeny) of MHAQ following the WHO larval bioassay method. After a 24 h exposure, the surviving larvae were transferred and allowed to emerge in emergence cages. The larvae were fed TetraMin® fish food, while the adult mosquitoes were fed 10% sucrose solution. After three to five days, thirty male and female mosquitoes were transferred into oviposition cages for cohabitation, and thirty minutes after combining, the mosquitoes were provided with guinea pig blood for 2 h. Fully engorged mosquitoes were then transferred to a new cage and supplied
with a 10% sucrose solution. Three days of blood meal was provided, fifteen females were transferred to individual plastic cups that were covered with a net and lined internally with a Whatman® No. 1 filter paper as an oviposition substrate. The females were allowed to oviposit their eggs for five days and the number of eggs was counted daily [19]. Eggs collected during the fecundity test were used in the fertility test by immersing the filter paper with the eggs into the tap water in the culture trays. The number of larvae that hatched was monitored and recorded, and the experiments were carried out at 26 ± 4 °C and 60 ± 20% RH with a 12:12 day:night photoperiod.

**Adult wing length**

It is known that the adult wing length correlates with the fecundity and body size of mosquitoes. After the adults emerged from the fertility studies, a total of thirty *Ae. aegypti* mosquitoes (males and females) were anesthetized and killed. All the right wings were removed, and the length of the wings was measured from the axial vein to the radius 1 (R1) vein using a stereomicroscope (100x).

**Small-scale field trials**

According to WHO guidelines, new products that have shown promising results in laboratory studies (Phase I) should be evaluated under Phase II. At this point, a proof of concept was required, i.e. the MHAQ could be transferred to other containers by wild mosquitoes and subsequently, the larvae could be killed. The study sites were located in the Petaling District, Shah Alam, Selangor, and two similarly isolated areas were selected: Dataran Automobil as the treatment area (19°57’05” S, 43°76’88”) and Seksyen 16 as the control area (19°57’05” S, 43°76’88”). The distance between the treatment and the control site was approximately 1.8 kilometers and both areas have been declared as dengue ‘hotspots’, with continuous dengue cases being reported and shared a similar housing structure with good access to sanitation. Dataran
Automobil was selected as a treatment area due to it being more vulnerable than Seksyen 16 and it is closer to our workstation in Shah Alam.

The trial consisted of a two-month pre-treatment period (November - December 2017), six months of treatment, and one month of post-treatment (January 2018 – July 2018). In the treatment and control areas, 48 ovitraps were placed in each area, with a total of 96 ovitraps [32-33]. All the ovitraps were randomly positioned in the potential container, such as under roofs, near vegetation sheds, water supplies, and near human activities areas. Each ovitrap cup was individually coded with labels to ensure it was placed at the same location in each sampling round and any missing ovitrap or paddle was replaced with a new one.

During the treatment phase, from the third month onwards, a total of 48 MHS stations were deployed at a distance of one to ten meters from the nearest ovitrap across the treatment site from January 2018 to June 2018. The stations were only deployed at the treatment site and serviced on a fortnightly basis to ensure that they were completely operational, that there was sufficient volume of the solution, and that any clogged devices were removed. The stations were then examined and the remaining solutions and paper substrates were collected and brought back to the laboratory for larval bioassay assessment.

The ovitraps and MHS were taken to the laboratory separately, and the contents of each MHS and ovitrap such as water, paddles, and paper substrates were transferred to an enamel pan to facilitate the observation of mosquito juveniles and attached eggs. All larvae were identified [36] and total intact eggs (hatched or unhatched) and live larvae were counted and recorded.

The impact of treatment using the MHS to deliver MHAQ to other ovitraps was determined using larval bioassays as defined in the WHO guidelines. In the case of ovitrap containers, water samples from treatment and control areas were tested at three different time points: pre-intervention, intervention, and post-intervention. In addition, although water samples from the MHS were available only during the treatment period, these samples were also tested. Larval bioassays were performed using late 3rd instar
larvae of the *Ae. aegypti*. Control treatments were treated with 199 ml tap water and 1 ml of acetone while three cups were set up using tap water and 20 larvae per bioassay as negative controls. Mortality was recorded every 24 h until adult emergence and larvae were also provided with food daily. In certain samples, pyriproxyfen contamination increased the larval development time from a typical 8 to 9 days up to 14 days, resulting in pupae death. The experiments were conducted at 26 ± 2 °C, 60 ± 20% RH, and preferably a photoperiod of 12 h light followed by 12 h dark.

**Statistical analysis**

All statistical analyses were conducted using the Statistical Package for the Social Science (SPSS) version 23. In each assay, the data sets were tested for normality distribution using the Shapiro-Wilk test. Prior to analysis, the log_{10} values of the data were obtained. If the data were normally distributed, a parametric test would be performed, followed by a Tukey post-hoc test. However, if the data were not normally distributed, a non-parametric test was applied.

All data for each treatment bioassays were presented as a mean ± SE unless specified otherwise. For the larvae bioassay test, data were analyzed using the Probit analysis. The EI was calculated using the following formula [38]:

\[
\text{Percentage of inhibition of emergence} = 100 - 100(T/C),
\]

where T is the number of emergence in treated containers, and C is the number of emergence in control containers. Control mortality of more than 5% was corrected using Abbott’s formula [39].

Mortality data for the larval bioassay was recorded and presented as a percentage, with all data calculated using the log-Probit analysis. Results were presented as LC_{50} (lethal concentration in ppm for 50% death) and LC_{90} (lethal concentration in ppm which caused 90% mortality).

The effective reduction (ER) percentage was calculated as:

\[
\text{ER} \% = \left[ \frac{\text{NC} - \text{NT}}{\text{NC}} \right] \times 100,
\]
where NC is the number of eggs in the control group and NT is the number of eggs in the treatment group. A student’s t-test was used to compare fertility, fecundity, and wing length of *Ae. aegypti* between the control and treated groups. A Mann-Whitney test was performed when the normality was not met.

The comparison of oviposition attractants was performed using a one-way ANOVA test followed by a Tukey post-hoc test. The impact of the oviposition site with MHAQ, HI, and TW was assessed with a one-way ANOVA test, followed by a Tukey post-hoc test where necessary. All the results of the analysis with \( p < 0.05 \) were considered statistically significant. For the residual activity trials, analysis of the concentration effects, pupal mortality, and their interactions was performed using two-way repeated measures ANOVA and the Greenhouse-Geisser correction. The transfer activities of MHAQ in the laboratory and field trials were analyzed for each concentration for successful adult emergence using a one-way ANOVA with a Tukey post-hoc test between the means (\( p < 0.05 \)).

**Results**

**Susceptibility of *Ae. aegypti* to MHAQ**

The response dose range was established based on the 3\(^{rd}\) instar *Ae. aegypti* larvae. Mortality of the *Ae. aegypti* was recorded approximately 24 h after exposure in the laboratory bioassay and it was observed that MHAQ effectively killed the *Ae. aegypti* larvae at 24 h exposure with a LC\(_{50}\) of 0.0903 ppm (95% CL = 0.0827 – 0.0986) and LC\(_{90}\) of 0.237 ppm (95% CL = 0.237 - 0.286). Meanwhile, the EI\(_{50}\) and EI\(_{90}\) of *Ae. aegypti* exposed with MHAQ were 0.323 ppb (95% CL = 0.065 - 0.89) and 0.102 ppb (95% CL = 0.059 - 0.141), respectively.

**Transfer of MHAQ from treated to untreated ovitraps**

The ability of one, three, and five mosquitoes to transfer MHAQ to the untreated containers was determined and it was found that larvae were significantly prevented from developing into adults
compared to the control groups (ANOVA, $F_{(6, 24)} = 3.97, p < 0.007$). For treatment groups, the five-mosquito group transferred the most MHAQ and had the highest EI compared to the other groups. However, there was no significant difference in the groups of three and five females at 40 ppm of MHAQ with an EI% between 93.3 – 100% (Fig. 3). Table 1 shows the exposure of different numbers of mosquitoes at oviposition sites treated with different concentrations of pyriproxyfen. The results revealed that there was no significant difference between the number of eggs laid in the treated and untreated water by a different number of mosquitoes. It was evident that even at high concentrations, MHAQ did not affect the number of eggs that had been laid.

*Anopheles aegypti* oviposition activities to MHAQ in competition with water

Three different types of bioassays were used to observe the oviposition preference of *Ae. aegypti* between MHAQ. For the first bioassay, oviposition sites were divided into either MHAQ, HI, TW a, or TW b. Gravid *Ae. aegypti* females laid their eggs in all the cups and a total of 2107 eggs were recorded. The maximum mean number of eggs laid was in the HI (365.00 ± 57.14), followed by TW b (191.75 ± 60.72), TW a (183.50 ± 44.58), and MHAQ (16.75 ± 6.93). There was a significant difference between the mean number of eggs in the MHAQ with HI and TW (ANOVA, $F_{(3,12)} = 13.003, p = 0.0004$). However, there was no significant difference observed between TW a, and TW b in this assay ($p > 0.05$) (Fig. 4a).

For the second bioassay, a comparison between four cups (three TW and one MHAQ) was conducted to evaluate the oviposition site preference of gravid *Ae. aegypti*, with eggs, also laid in all four cups. However, only 4.2% of eggs were deposited in a cup containing MHAQ (MA = 37.5 ± 8.93) while 95.8% was deposited in the cups filled with tap water (TW a: 304.25 ± 37.82; TW b: 274.5 ± 48.56; and TW c: 172.25 ± 28.83) (Fig. 4b). There was a significant difference between the two types (MHAQ and TW) of attractants used for oviposition (ANOVA, $F_{(3,12)} = 12.359, p = 0.001$). However, there was no significant difference in the mean number of eggs collected in the TW a and TW c ($p > 0.05$).
In the third bioassay, three cups were filled with MHAQ a, MHAQ b, MHAQ c, and one with TW, with eggs oviposited in all the cups. A total of 2269 eggs were laid in all the cups, with 68% of the eggs in the cups baited with MHAQ solutions and 32% of the eggs in the cups baited with TW, resulting in the highest number of eggs laid in the TW cups. Moreover, there was no significant difference between the mean number of eggs collected across the treatments (ANOVA, $F_{(3,12)} = 0.442, p = 0.727$) (Fig. 4c).

**Residual larvicide activity of MHAQ**

From Day 10 to Day 90, there was greater efficacy of the MHAQ at the higher concentrations of 40 ppm and 20 ppm. At the lower concentrations (0.5 ppm and 1.0 ppm), there was more than 90% mortality until Day 30 until a less than 80% decrease in pupal mortalities on Day 40. There was no pupal mortality on day 90. Based on laboratory trials, the residual activity of the MHAQ achieved over 80% mortality for 30 days and continued for 90 days (Fig. 5). The interaction between the MHAQ concentration and time was statistically significant based on a repeated measure ANOVA and the Greenhouse-Geisser correction on the number of pupal mortalities (time, $F_{(3.77, 94.21)} = 547.21, p < 0.001$; treatment, $F_{(4, 25)} = 7020.44, p < 0.001$; treatment x time, $F_{(15.07, 94.21)} = 205.71, p < 0.001$).

**The effect of MHAQ on fecundity, fertility, and wing length**

It was found that the $LC_{50} = 0.0903$ ppm significantly reduced the number of eggs laid in the treatment group compared to the control group (Student’s $t$-test: $t = 7.509; df = 18; p < 0.05$). The mean number of eggs laid by *Ae. aegypti*, was $53.70 \pm 13.64$, compared to $112.80 \pm 20.82$ in the control group ($p < 0.05$). (Student’s $t$-test for a single sample: $t = 8.355; df = 10; P <0.001$), indicating a 50% reduction in the mean number of eggs laid in the treatment group compared to the control group.

There was also a significant difference (Student’s $t$-test: $t = -5.489; df = 18; p < 0.05$) in the percentage of eggs hatching in the control group (92.80%) and the treatment group that was exposed to a
sublethal dose of MHAQ (70.67%). The ER% was ≈ 23.46, which was significantly different from zero (Student t-test for a single sample: \( t = 5.023; \text{df} = 10; p < 0.001 \)), suggesting a decrease in the rate (percent) of hatching in the treatment group by 20% compared to the control group. On the other hand, the wing lengths of male mosquitoes that had the sublethal treatment were significantly different from the wing lengths of male mosquitoes in the control group (Mann-Whitney U-test: \( U = 2.5, Z = -6.6635, p < 0.0001 \)). The effects were similar for female mosquitoes, where the wing lengths of those that had the sublethal treatment were significantly different than those in the control group (Mann-Whitney U-test: \( U = 0, Z = -6.662, p < 0.0001 \)) (Table 2).

**Efficacy of small-scale field trials**

Egg collections were carried out from both ovitrap and MHS in order to determine the preference of the mosquitoes between TW and MHAQ. During the intervention period, MHS with MHAQ formulations was most effective in attracting *Aedes* compared to ovitrap, with a significantly greater collection in MHS (1176.15 ± 57.84) than in ovitrap (858.82 ± 59.87) (ANOVA: \( F(_{1, 94}) = 14.57, p < 0.001 \)). After four weeks of MHS implementation, an increased number of eggs collected was observed in week 12 and this was consistently observed until the end of week 30. Based on a repeated measure ANOVA and the Greenhouse-Geisser correction, there was a significant difference in the average eggs that were collected between multiple time points (\( F(7.88, 740.75) = 15.24, p < 0.001 \); treatment x time, \( F(7.88, 740.75) = 3.67, p < 0.001 \)). In addition, the number of eggs collected fluctuated with some variation due to other environmental factors (Fig. 6).

In the small field trials, autodissemination of MHAQ was detected in the ovitraps. In the ovitrap and MHS, the mortalities of pupas exposed to the water sample during the intervention periods were significantly higher than in the control samples, where pupal mortality in the ovitrap was 28.07 ± 4.42% at week 10, which was consistent during the trials, and peaked at 42.63 ± 11.46% at week 26. There was
a small decrease in mortality at week 14 (14.61 ± 2.03). After 12 weeks of intervention, the overall mortality in the trials was 27.01 ± 1.8% and 100% pupal mortality was observed in both the ovitraps and the MHS (Fig. 7).

Discussion

Dengue fever is a disease caused by mosquitoes that significantly impact human health. However, existing vector management methods have failed to reduce dengue infections, indicating that these methods may not be sufficient and require improvements. Pyriproxyfen autodissemination is a novel strategy for dispersing pyriproxyfen into oviposition containers through the manipulation of the ‘skip oviposition’ behavior of mosquitoes. The study aimed to determine the effectiveness of MHS using autodissemination strategies based on laboratory and small-scale field studies.

Multiple choice of egg-laying site tests and larval bioassays revealed that *Ae. aegypti* was highly susceptible to low concentrations of MHAQ, which affected the fecundity, fertility, and wing size of the mosquitoes. In this study, MHAQ was more effective in killing *Ae. aegypti* larvae after a 24-h exposure, with the LC$_{90} = 0.237$ ppm, which was lower compared to a previous study (LC$_{90} = 10$ ppm) [40]. The EI$_{50}$ rate obtained was 0.323 ppb, which was consistent with other studies that reported low EI$_{50} = 0.56$ ppb [24], 0.353 ppb, 0.219 ppb [41] and 0.008 ppb [42]. Furthermore, Paul *et al.* [43] showed that pyriproxyfen effects were more toxic against *Ae. aegypti* than other insecticides (methoprene, diafenthiuron, and tebufenozide). The dose-response test result obtained in this study differed from others, which could be due to the mosquito strain selections used in the experiments [44], different pyriproxyfen formulations [45], the material of the test containers [46], and experimental conditions. It was reported by Suman *et al.* [46] that the efficacy of pyriproxyfen was positively associated with the type of substrate used during the study. The LC$_{50}$ value in tires was found to be 50-fold higher compared to glass containers.
and it has been suggested that the pyriproxyfen was adsorbed by the substrate used [46]. There have so far been no reports of *Aedes* spp. resistance to pyriproxyfen in Malaysia, thus it can be used as an alternative insecticide in dengue control programs [47].

In the present study, MHAQ exposure at the selected dose significantly reduced the fecundity, fertility, and wing length of the *Ae. aegypti* mosquitoes. The size of female mosquitoes is important as larger females produce more eggs and contribute more to the mosquito populations. Exposure to pyriproxyfen has been demonstrated to affect the reproductive capacity of *Aedes* spp. through inhibition of vitellogenesis during egg formation [48], which is desirable since the production of a high number of eggs and optimal fertility are two key factors that influence the survival of mosquitoes [49]. Moreover, Suttana et al. [50] found a reduction in fertility and fecundity after only five minutes of exposure to pyriproxyfen. On the other hand, although there was no significant difference recorded in the number of eggs laid, Rhyne et al. [51] reported a lower hatching rate in treated containers compared to the controls. However, the effects of pyriproxyfen may vary among mosquitoes depending on exposure time, the concentration used, mode of delivery, and other factors [52]. Pyriproxyfen also affects the fertility and fecundity rates of the mosquitoes, however, the mechanism of action remains uncertain and requires further investigation [53-55].

The study conducted on horizontal transfer of MHAQ was crucial as it demonstrated successful autodissemination by the adult *Ae. aegypti* from treated to untreated sites. It would also be useful to target the gravid female mosquitoes at their resting sites as this may increase the amount of insecticide that can be transferred to other oviposition sites. In addition, Chism et al. [25] found that the larval mortality in an untreated site could be associated with the number of eggs laid and the residence time in the containers. The longer the time it takes for mosquitoes to lay eggs, the greater their chances of depositing more MHAQ at the untreated sites. The findings of this study provided evidence, in principle, that the MHAQ
solution can be significantly transferred from contaminated containers to gravid females, who then transfer it to other oviposition sites. It was found that autodissemination activity increased with the number of female mosquitoes and the highest EI was observed when five *Ae. aegypti* were introduced to 20 and 40 ppm of MHAQ during the assays. In order to provide optimal control, the MHAQ needs to be disseminated by a large number of mosquitoes in particular sites, with higher numbers of mosquitoes thought to be able to transfer more chemicals compared to smaller numbers. During these trials, it was presumed that the gravid females would be more contaminated with higher MHAQ concentrations over time during oviposition.

Autodissemination using a powdered formulation of pyriproxyfen is impractical, as its application causes the accumulation of granules at the bottom of the container over some time [56]. Because of this, the MHAQ solution was evaluated concerning its capability in transferring different concentrations of pyriproxyfen to other containers under laboratory conditions. In addition, this was also the first report suggesting the autodissemination approach using commercial MHAQ treated water to control *Ae. aegypti* populations.

In comparison to tap water and MHAQ, more gravid females laid their eggs in hay infusion. MHAQ has an attractant effect, similar hay infusion, and has been considered the “gold standard” for collecting and attracting mosquitoes [57]. Despite the preference for hay infusion, it was observed that *Ae. aegypti* oviposited eggs in all the treated and untreated ovitraps. Although MHAQ does not have a strong repellent effect, the females would still have an equal preference to lay their eggs in MHAQ and water under natural conditions. Besides that, the laboratory test containers were chemically treated, which could a reason why mosquitoes avoided laying their eggs in the containers and did not spend enough time in the cups. Other studies found that microbial activities in each oviposition bioassay influenced mosquito oviposition preference [58-59]. Thus, it remained unclear which of the numerous unknown degradants, mechanisms, and sources of the substances reduced the attraction of *Ae. aegypti* to MHAQ with respect
to tap water in our study. Physicochemical aspects of the aquatic medium, visual cues, and the likelihood or possibility of adverse effects on larval development have been reported to be major factors affecting egg deposition decisions of female mosquitoes [60]. This study is the first report of MHAQ effect on the ovipositional activity of mosquitoes and it would be essential to determine which of the chemical structures and compounds in the products affect the oviposition preference.

These findings also revealed the existence of the previously reported “skip oviposition” behavior. Furthermore, the effectiveness of the autodissemination technique highly depends on the *Aedes* mosquitoes acting as a mode of transportation to disseminate insecticide to the other containers [61]. The females distributed their eggs in multiple containers to avoid overcrowding in the same container, as well as reducing the possibilities of losing all offspring due to site elimination, to ensure the survival of their progeny. This finding was similar to the study conducted by Wong *et al.* [62] in Iquitos, where female mosquitoes laid eggs in all containers, but other parameters (food resources, size, temperature) were strictly assessed. Although gravid female *Ae. aegypti* and *Ae. albopictus* distribute their eggs at many sites, this behavior was not mutually exclusive as it may differ over time depending on the available suitable containers [63].

This study also discovered that MHAQ formulations have repellent properties against *Ae. aegypti* in laboratory settings, leading to a reduction in MHAQ efficacy. These are the first reported trials that assessed the efficacies of the MHS and MHAQ as new products. According to Vontas *et al.* (44), evaluation of all new vector control tools in testing pathway phases must be performed to ensure that one or two primary effects are obtained as a result of laboratory testing. However, there are a few criteria that need to be considered if the new product to be tested in field trials. One of the criteria was to employ the ‘stop and go’ principle, which states that if a new product assay is not optimum yet but has passed the minimum efficacy threshold in the laboratory, there is merit to proceed to the next level of testing i.e. small-scale field evaluation. Furthermore, if the product has multiple properties (e.g. reduce fertility or
repellence) and only displayed one action with an acceptable passing “indicative criteria”, it is likely that extra-combined effects can be measured at a later phase.

Nevertheless, results obtained from the laboratory assessment must be interpreted with caution as the tests were conducted in a well-controlled environment when making operational field decisions. A variety of biological parameters including type of strain and preference of egg-laying oviposition, as well as environmental parameters such as temperature, humidity, rainfall, and sunlight conditions can all affect the efficacy of the product [64-66]. Despite laboratory tests revealing the minor repellent impact of MHAQ against mosquitoes, the number of eggs obtained in small-scale field trials was higher than the gold standard (ovitrap). Other parameters such as the chemical transference by mosquitoes and the effect on biological parameters of mosquitoes also indicate a promising outcome. The MHS has a potential that could potentially be used as an autodissemination station in future control efforts. Moreover, this is the first report of the effect of MHAQ on the ovipositional activity of mosquitoes. It is essential to determine the chemical structures and compounds in the products that affect the oviposition preference.

The beneficial residual impact of MHAQ on *Ae. aegypti* is encouraging and has presented a prolonged action of 22 weeks by killing 100% of the larvae. With respect to the residual larvicidal activity of the commercial MHAQ solutions, concentrations of 20 and 40 ppm were sufficient to produce 100% mortality up to 90 days. Since the MHAQ formulation can be kept inside the MHS for up to two months before completely evaporating, MHAQ needed to remain active for at least the two-month period of the treatments. This slow-release formulation should be able to exhibit residual larvicidal activity to prevent the emergence of mosquitoes and, subsequently, reduce labor costs and spraying activities. Furthermore, WHO considers 80% or higher mosquito mortality to be an effective insecticide. However, it was noted that the exposure of treated containers under laboratory settings may not reflect actual field conditions as environmental factors such as direct rainfall, organic matter, exposure to sunlight, and water exchange...
may reduce the efficacy of MHAQ. Therefore, further studies on MHAQ residual activity should be conducted under a wider range of settings.

The findings in the small-scale field trials were consistent with previous studies that demonstrated that MHS was an efficient tool to monitor and trap *Aedes* spp. mosquitoes [67-68]. The small-scale field trials showed that MHS consuming commercial MHAQ was highly attractive compared to conventional ovitraps among local *Aedes* mosquitoes. Our trials were located in the middle of the city with a high range of mosquito population, with no walls or barriers in place to prevent mosquitoes from migrating into the study area from nearby. These mosquitoes may potentially replace the local mosquito population [69], thus laying their eggs inside the MHSs, ovitrap, or both as their first choice before they reach other container habitats. It is important to address this significant factor, especially in the open field trials [70]. Apart from varying moisture levels, visual and heat cues may also affect mosquito recognition of hosts, in particular environments that produce different results. Thus, further studies are still required on whether the MHAQ is consistently more effective in different settings.

In a field setting, the efficiency of MHAQ dissemination from MHS to ovitrap was demonstrated. The occurrence of MHAQ in the ovitrap was determined, with pupal mortality ranging from 14.6 % to 42.6 %. It was discovered that no larvae of *Aedes* spp. were present in the MHS stations treated with MHAQ during the MHS implementation period, leading to the hypothesis that the MHAQ formulation killed all of the hatched larvae and demonstrated the effectiveness against *Ae. aegypti* 1st instar larvae. Our previous study using residual activity trials found that MHAQ (20 and 40 ppm) had 100% mortality against *Aedes* mosquitoes for up to 3 months, which implied that the 100% mortality observed in the water sample collected from MHS (treatment) in the small-scale field trials was also influenced by the residual effect. Aside from that, the initial concentration of MHAQ was maintained by the replenishment of the formulation every two weeks. Semi-field and field trials have demonstrated that *Aedes* spp. can transfer pyriproxyfen from the treated containers to other larval oviposition sites, which have caused a high range
of EI rates on the mosquitoes. Suman *et al.* [71] obtained 50.4% pupal mortality against *Ae. albopictus* with a dissemination range of up to 200 m in residential areas while Lloyd and colleagues also reported autodissemination activities within a range of up to 200 m from the autodissemination vases that can be effectively used for five weeks against *Ae. albopictus* larvae [72]. Thus, it is likely that most studies used a large amount of pyriproxyfen to increase the impact of autodissemination under semi-field and field conditions [73].

The occurrence of various factors has limited the capability to investigate a broader aspect against the local mosquito population. In addition, incoming mosquitoes may also play an important role in increasing the coverage of pyriproxyfen dissemination, which, unfortunately, may lead to the failure of specific experiments [74]. The oviposition preference of mosquitoes has a complex effect in understanding local populations following the use of a new pyriproxyfen formulation with a potent attractant developed by the manufacturer. Certain studies have reported that *Aedes* spp. express oviposition behavior for certain types of attractants, such as bamboo leaf infusions [75], octenol [76], and yeast-produced CO\textsubscript{2} [77], and these substrates should be taken into consideration when MHAQ is used due to their possibility of enhancing the insecticide transference success rate. Furthermore, further investigation on all aspects of the oviposition substrates that act as important oviposition cues should be performed in order to improve the MHS efficacy before it can be considered as an alternative tool in vector control management.

**Conclusions**

The findings in this study demonstrated that MHS has the potential for use as an autodissemination station in future dengue control programs. Most of the parameters tested in our laboratory trials showed encouraging results, despite the formulation of the MHAQ showing a weak attractant effect on the *Ae. aegypti*. However, small-scale field trials have shown that MHAQ was more attractive than ovitraps, with a higher number of eggs collected. Further research should focus on the identification of the compound
An evaluation of a Mosquito home system for controlling Aedes aegypti

responsible for attracting *Aedes* spp. mosquitoes as well as their underlying mechanisms. In addition, it is essential to improve the efficacy of MHS, particularly in semi-field and field conditions, as well as the discovery of new and powerful combinations of MHAQ solutions. The combination of different techniques and approaches may prove to be a powerful alternative tool for vector control programs, particularly in Malaysia.

**Abbreviations**

ANOVA: analysis of varians; EI: emergence inhibition; ER: effective reduction; HI: hay infusion; MHAQ: Mosquito home aqua; MHS: Mosquito home system; RH: relative humidity; TW: tap water; WHO: World Health Organization

**Acknowledgments**

We would like to thank the Director General of Health Malaysia for his permission to publish this article. We wish to thank One Team Networks Sdn Bhd, Malaysia for providing the pyriproxyfen and Mosquito home system used in this study. We also extend our gratitude to Ms. Rawaida, Ms. Siti Rahayu and Ms. Hafizah for field sampling. We are grateful to Dr. Vanitha Mariappan and Mr Steve Page for proofreading of the manuscript.

**Funding**

This research was funded by Dengue Tech Challenge 2016 Grant, under the Newton-Ungku Omar Fund Partnership (AIM/ PlaTCOM/ HIP2/ CCGF/ 2016/ 088). The grant is funded by the Malaysia Industry-Government Group for High Technology (MIGHT) and the United Kingdom Department for Bussiness, Energy, and Industrial Strategy, delivered by the British Council and PlatCOM Ventures.
Availability of data and materials

Data supporting the conclusions of this article are included within the article. The datasets used and analyzed during the present study are available from the corresponding author upon reasonable request.

Author Contributions

NWA, HFO, AMMN contributed to the concept and study design. AMMN, NSA, AAZ and AML performed the experiments and sample collection. YL, DG, AML and AMMN analysed the data. HFO, YL, DG, JCSM, MS, RH critically revised and edited the manuscript. AMMN wrote the first draft of the manuscript. HFO, MS and RH supervised the project. All authors have read and agreed to the final version of the manuscript.

Ethics approval and consent to participate

No human participants, human data or human tissue were used in the present study. Insects were fed on guinea pig according to a protocol approved by Research Ethics Committee, The National University of Malaysia (Ref No: UKMPPI/111/8/JEP-2016-393). This study is registered with the National Medical Research Registered and approved for publication by the Director General of Health, Ministry of Health Malaysia (NMRR ID: NMRR-21-203-58556)

Consent for publication

Not applicable
Conflicts of Interest

The authors declare no conflict of interest and the funders had no role in the design of the study; in the
collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish
the results.

Author details

1 Center for Toxicology and Health Risk, Faculty of Health Sciences, Universiti Kebangsaan Malaysia,
50300 Kuala Lumpur, Federal Territory of Kuala Lumpur.

2 Medical Entomology Unit, Infectious Disease Research Centre, Institute for Medical Research,
National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia.

3 Phytochemistry Unit, Herbal Medicine Research Centre (HMRC), Institute for Medical Research,
National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia.

4 Department of Mathematics and Statistics, University of Strathclyde, Glasgow G1 1XH, UK.

5 Department of Biomedical Science, Faculty of Medicine and Health Science, Universiti Putra
Malaysia, 43400 Serdang, Selangor.

6 Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, 50600
Cheras, Kuala Lumpur.

References

1. Chew CH, Woon YL, Amin F, Adnan TH, Wahab AHA, Ahmad ZE, et al. Rural- urban comparison
of dengue seroprevalence in Malaysia. BMC Public Health. 2016; 16: 824.
2. Yusoff HM. National Dengue Programme in Malaysia, In: Asia-Pacific Dengue Program Managers Meeting, Singapore, 5 - 9 May 2008. World Health Organization -Western Pacific Region; 2008. p. 83-86.

3. Capeding MR, Tran NH, Hadinegoro SRS, Muhamad Ismail HIHJ, Choypitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: Aphase 3, randomised, observer-masked, placebo-control trials. Lancet. 2014; 384(9951): 1358-65.

4. Thomas SJ, Yoon IK. A review of dengvaxia® development to deployment. Hum Vacce Immunother. 2019; 15(10): 2295-2314.

5. Silveira LTC, Tura B, Santos M. Systematic review of dengue vaccine. BMC Infect Dis. 2019; 19:750.

6. Robinson ML. Durbin AP. Dengue vaccines: implication for dengue control. Curr Opin Infect Dis. 2017; 30(5): 449-454.

7. Othman H, Nordin SA, Rashid NA, Abas MBH, Hod R, Sahani M. Dengue free community as an approach for understanding the value and challenges of inter-agencies partnerships in an intervention program. IJPH. 2017; 4(6): 1810-1826.

8. Roiz D, Wilson AL, Scoot TW, Fonseca DM, Jourdain F, Muller F. et al. Integrated Aedes management for the control of Aedes borne diseases. PloS Negl Trop Dis. 2018; 12(12): e0006845.

9. Vythilingam I, Wan-Yusoff WS. Dengue vector control in Malaysia: Are we moving in the right direction. Trop Biomed. 2017; 34(4): 746-758.

10. Francis S, Saavedra-Rodriguez K, Perera R, Paine M, Black WC, Delgoda R. Insecticide resistance to permethrin and malathion and associated mechanisms in Aedes aegypti mosquitoes from St. Andrew Jamaica. PLoS ONE. 2017; 12(6): e0179673.

11. Goindin D, Delannay C, Gelasse A, Ramdini C, Gaude T, Faucon F, et al. Level of insecticide resistance to deltamethrin, malathion, and temephos, and associated mechanisms in Aedes aegypti
mosquitoes from the Guadeloupe and Saint Martin Islands (French West Indies). Infect Dis Poverty. 2017; 6:38.

12. Moyes CL, Vontas J, Martins AJ, Ng LC, Koou SY, Dusfour I, et al. Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. PLoS Negl Trop Dis. 2017; 11(7): e0005625.

13. Hidayatulfathi O, Shamsuddin AF, Rajab NF, NorZafirah AB, Nur Hazwani AA, Nur Afriza MFO, et al. Three repellent gels that contain essential oils from local Malaysian plants against dengue vector. Trop Biomed. 2017; 34(3): 540-649.

14. WHO. Guidelines for drinking water quality, 3rd edition, including first and second agenda. Geneva: World Health Organization; 2008.

15. Deviller J. Fate of pyriproxyfen in soils and plants. Toxic. 2020; 8:20.

16. Santos VSV, Limongi JE, Pereira BB. Association of low concentrations of pyriproxyfen and Spinosad as an environment-friendly strategy to rationalize Aedes aegypti control programs. Chemosphere. 2020;247: 125795.

17. WHO. Pyriproxyfen in drinking-water. Background document for development. WHO guidelines for drinking-water quality. Geneva: World Health Organization; 2008. WHO/SDE/WSH/03.04/113.

18. Abad-Franch F, Zamora-Perea E, Ferraz G, Padilla-Torres SD, Luz SLB. Mosquito-disseminated pyriproxyfen yields high breeding-site coverage and boosts juvenile mosquito mortality at the neighborhood scale. PLoS Negl Trop Dis. 2015; 9(4): e0003702.

19. Caputo B, Lenco A, Cianci D, Pombi M, Petrarca V, Baseggio A, et al. The “autodissemination” approach: a novel concept to fight Aedes albopictus in urban areas. PLoS Negl Trop Dis. 2012; 6(8): e1793.

20. Devine GJ, Zamora-Perea E, Killeen GF, Stancil JD, Clark SJ, Morrison AC. Using adult mosquitoes to transfer insecticides to Aedes aegypti larval habitats. PNAS. 2009; 106(28): 11530-11534.
21. Suman DS, Wang Y, Faraji A, Williams GM, Williges E, Gaugler R. Seasonal field efficacy of pyriproxyfen autodissemination stations against container-inhabiting mosquito Aedes albopictus under different habitat conditions. Pest Manag Sci. 2018; 74(4): 885-895.

22. Ahmad Mohiddin MN, David G, Asmalia ML, Mazrura S, Rozita H, Hidayatulfathi O. A review: Autodissemination of pyriproxyfens as novel strategy to control dengue outbreaks. Pertanika J. Sci. & Technol. 2020; 28(4): 1117-1140.

23. Chandel K, Suman DS, Wang Y, Unlu I, Williges E, Williams GM, et al. Targeting a hidden enemy: pyriproxyfen autodissemination strategy for the control of the container mosquito Aedes albopictus in cryptic habitats. PLoS Negl Trop Dis. 2016; 10(12): e0005235.

24. Itoh T. Utilization of bloodfed females of Aedes aegypti as a vehicle for the transfer of the insect growth regulator, pyriproxyfen, to larval habitats. Trop Med. 1994; 36(4): 243-248.

25. Chism BD, Apperson CS. Horizontal transfer of the insect growth regulator pyriproxyfen to larval microcosm by gravid Aedes albopictus and Ochlerotatus triseriatus mosquitoes in the laboratory. Med Vet Entomol. 2003; 17(2): 211-20.

26. Abad Franch F, Perea EZ, Luz SLB. Mosquito-disseminated insecticide for citywide vector control and its potential to block arbovirus epidemics: entomological observations and modelling results from Amazonian Brazil. Plos Med. 2017; 14(1): e1002213.

27. Yazan LS, Paskaran K, Gopalsamy B, Majid RA. Aedestech Mosquito Home System prevents the hatch of Aedes mosquito eggs and reduces its population. Pertanika J. Sci. & Technol. 2020; 28(1): 263-278.

28. WHO. Monitoring and managing insecticide resistance in Aedes mosquito populations, Interim guidance for entomologists. WHO Department of Control of Neglected Tropical Disease and Global Malaria Programme, Geneva: World Health Organization. 2016. WHO/ZIKV/VC/16.1.
29. Ahmad-Azri M, Syamsa RA, Ahmad-Firdaus MS, Aishah-Hani A. A comparison of different types of ovitraps for outdoor monitoring of *Aedes* mosquitoes in Kuala Lumpur. Trop Biomed. 2019; 36(2): 335-347.

30. Ali R, Azmi RA, Ahmad NW, Hadi AA, Muhamed KA, Rasli R, et al. Entomological surveillance associated with human zika cases in Miri Sarawak, Malaysia. Am J Trop Med Hyg. 2020; 102(5): 964-970.

31. Sihuincha M, Zamora-Perea E, Orellana-Rios W, Stancil JD, Lopez-Sifuentes V, Vidal-Ore C, et al. Potential use of pyriproxyfen for control of *Aedes aegypti* (Diptera: Culicidae) in Iquitos, Peru. J Med Entomol. 2005; 42(4): 620-630.

32. Suman, DS, Wang Y, Faraji A, Williams GM, Williges E, Gaugler R. Seasonal field efficacy of pyriproxyfen autodissemination stations against container-inhabiting mosquito *Aedes albopictus* under differeny habitat conditions. Pest Manag Sci. 2018; 74(4): 885-895.

33. Dieng H, Rajasaygar S, Ahmad AH, Rawi CSM, Ahmad H, Satho T, et al. Indirect effects of cigarette butt waste on the dengue vector *Aedes aegypti* (Diptera: Culicidae). Acta Trop. 2014; 130: 123-130.

34. Satho T, Dieng H, Ahmad MHI, Ellias S, AbuHassan A, Abang F, et al. Coffee and its waste repel gravid *Aedes albopictus* females and inhibit the development of their embryos. Parasit Vectors. 2015; 8: 272.

35. Zuharah WF, Abhirami R, Dieng H, Thiagaletchumi M, Fadzly N. Evaluation of sublethal effect of Ipomoea cairica Linn. Extract on life history traits of dengue vectors. Rev Inst Med Trop Sao Paulo. 2016; 58: 44.

36. Cheong WH, Mahadevan S. Entomological charts for teaching. Division of Medical Entomology, IMR: Kuala Lumpur: 1970.

37. Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019; 22(1): 67-72.
38. WHO. Efficacy-testing of traps for control of Aedes spp. mosquito vectors. Geneva: World Health Organization. 2018. WHO/CDS/NTD/VEM/2019.06.

39. Abbott WS. A method of computing the effectiveness of an insecticide. J Am Mosq Control Assoc. 1925; 3: 302-3.

40. Fiaz M, Martinez LC, Plata-Rueda A, Gonzalves WG, Souza DLL, Cossolin JFS, et al. Pyriproxyfen, a juvenile hormone analog, damage midgut cells and interferes with behaviors of *Aedes aegypti* larvae. PeerJ. 2019; 7: e7489.

41. Carvalho BL, Germano RNL, Braga KML, Araujo ERF, Rocha DA, Obara MT. Susceptibility of *Aedes aegypti* populations to pyriproxyfen in the Federal District of Brazil. Rev Soc Bras Med Trop. 2020; 53: e20190489.

42. Chen YA, Lai YT, Wu KC, Yen TY, Chen CY, Tsai KH. Using UPLC-MS/MS to evaluate the dissemination of pyriproxyfen by *Aedes* mosquitoes to combat cryptic larval habitats after source reduction in Kaohsiung in Southern Taiwan. Insect. 2020; 11: 251.

43. Paul A, Harrington C, Scott JG. Evaluation of novel insecticides for control of dengue vector *Aedes aegypti* (Diptera: Culicidae). J Med Entomol. 2006; 43(1): 55-60.

44. Vontas J, Moore S, Immo K, Ranson H, Lindsay S, Lengeler C, et al. Framework for rapid assessment and adoption of new vector control tools. Trends Parasitol. 2014; 30(4): 191-204.

45. Kawada H, Shono Y, Abe Y. Laboratory evaluation of insect growth regulators against several species of anopheline mosquitoes. Jpn J Sanit Zool. 1993; 44(4): 349-359.

46. Suman DS, Wang Y, Dong L, Gaugler R. Effects of larval habitat substrate on pyriproxyfen efficacy against *Aedes albopictus* (Diptera: Culicidae). J Med Entomol. 2013; 50(6): 1261-1266.

47. Lau KW, Chen CD, Lee HL, Norma-Rashid Y, Sofian-Azirun, M. Evaluation of insect growth regulators against field-collected *Aedes aegypti* and *Aedes albopictus* (Diptera: Culicidae) from Malaysia. J Med Entomol. 2015; 52(2): 199-206.
48. Harburguer L, Zerba E, Licastro S. Sublethal effect of pyriproxyfen released from a fumigant formulation on fecundity, fertility and ovicidal action in *Aedes aegypti* (Diptera: Culicidae). J Med Entomol. 2014; 51(2): 436-443.

49. Devi U, Bora D. Growth inhibitory effect of phenolic extract of *Ziziphus jujube* Mill. in dengue vector *Aedes aegypti* (L) in parent and F1 generation. Asian Pac J Trop Med. 2017; 10(8): 787-791.

50. Suttana S, Yanola J, Lumjuan N, Somboon P. The efficacy of pyriproxyfen-treated resting boxes on the reproductivity of *Aedes aegypti* (Diptera: Culicidae) in the laboratory. Trop Biomed. 2019; 36(2): 514-530.

51. Rhyne MN, Richards SL. Impact of the insect growth regulator pyriproxyfen on immature development, fecundity and fertility of *Aedes albopictus*. J Am Mosq Control Assoc. 2020; 36(1): 11-15.

52. Maoz D, Ward T, Samuel M, Muller P, Runge-Ranzinger S, Toledo J, et al. Community effectiveness of pyriproxyfen as a dengue vector control method: A systematic review. PloS Negl Trop Dis. 2017; 11(7): e0005651.

53. Yadav K, Dhiman S, Acharya B, Ghorpade RR, Sukumaran D. Pyriproxyfen treated surface exposure exhibits reproductive disruption in dengue vector *Aedes aegypti*. PLoS Negl Trop Dis. 2019; 13(11): e0007842.

54. Ahmad TH, Saunders TR, Mullins D, Rahman MZ, Zhu J. Molecular action of pyriproxyfen: role of the Methoprene-tolerant protein in the pyriproxyfen-induced sterilization of adult female mosquitoes. PLoS Negl Trop Dis. 2020; 14(8): e0008669.

55. Harris C, Lwetoijera DW, Dongus S, Matowo NS, Lorenz LM, Devine GJ, et al. Sterilising effects of pyriproxyfen on *Anopheles arabiensis* and its potential use in malaria control. Parasit Vectors. 2013; 6: 144.
56. Ponlawat A, Fansiri T, Kurusarttra S, Pongsiri A, McCardle PW, Evans BP, et al. Development and evaluation of a pyriproxyfen-treated device to control the dengue vector, *Aedes aegypti* (L.) (Diptera: Culicidae). Southeast Asian J Trop Med Public Health. 2013; 44(2): 167-78.

57. Silva WA, Silva, JS, Ferrerira FAS, Rodrigues IB, Tadei WP, Zequi JAC. Oviposition of *Aedes aegypti* Linnaeus, 1762 and *Aedes albopictus* Skuse, 1894 (Diptera: Culicidae) under laboratory and field conditions using ovitraps associated to different control agents, Manaus, Amazonas, Brazil. Rev Bras Entomol. 2018; 62(4): 304-310.

58. Girard M, Martin E, Vallon L, Raquin V, Bellet C, Rozier Y, et al. Microorganisms associated with mosquito oviposition sites: Implications for habitat selection and insect life histories. Microorganisms. 2021; 9: 1589.

59. Bennett KL, Martinez CG, Chin Y, Saltonstall K, McMillan WO, Rovira JR et al. dynamics and diversity of bacteria associated with the disease vectors *Aedes aegypti* and *Aedes albopictus*. Sci Rep. 2019; 9: 12160.

60. Ponnusamy L, Schal C, Wesson DM, Arellano C, Apperson CS. Oviposition responses of *Aedes* mosquitoes to bacterial isolates from attractive bamboo infusion. Parasit Vectors. 2015; 8: 486.

61. Seixas G, Paul REL, Pires B, Alves G, Jesus A, Silva AC. et al. An evaluation of efficacy of the autodissemination technique as a tool for *Aedes aegypti* control in Madeira, Portugal. Parasites & Vectors. 2019; 12: 202.

62. Wong J, Stoddard ST, Astete H, Morrison AM, Scott TW. Oviposition site selection by the dengue vector *Aedes aegypti* and its implications for dengue control. PLoS Negl Trop Dis. 2011; 5(4): e1015.

63. Nazni WA, Bandara MRSS, Azahari AH, Craig RW, Lee HL. Skip oviposition behavior of laboratory, field and transgenic strain of *Aedes aegypti* (L.). Southeast Asian J Trop Med Public Health. 2016; 47(4): 680-690.
64. Richards SL, Byrd BD, Reiskind MH, White AV. Assessing insecticide resistance in adult mosquitoes: perspectives on current methods. Environmental Health Insight; 2020, 14: 1-7.

65. Marcombe S, Chonephetsarath S, Thammavong P, Brey PT. Alternative insecticides for larval control of the dengue vector *Aedes aegypti* in Lao PDR: insecticide resistance and semi-field trial study. Parasites & Vectors; 2018, 11: 616.

66. Brady OJ, Johansson MA, Guera CA, Bhatt S, Golding N, Pigott DM, et al. Modelling adult *Aedes aegypti* and *Aedes albopictus* survival at different temperatures in laboratory and field setting. Parasites & Vectors; 2013, 6: 351.

67. Yazan LS, Paskaran K, Gopalsamy B, Majid RA. Aedestech Mosquito Home System prevents the hatch of *Aedes* mosquito eggs and reduces its population. Pertanika J. Sci. & Technol; 2020, 28(1): 263-278.

68. Ngosom AMM, Hanif WNW, Lasim AM, Sahani M, Hod R, Othman H. A semi-field and field simulation using autodissemination methods against dengue vector *Aedes aegypti* (Linnaeus) (Diptera: Culicidae). Serangga; 2020, 25(3): 12-34.

69. Jiggins FM. The spread of Wolbachia through mosquito populations. PLoS Biol; 2017, 15(6): e2002780.

70. Unlu I, Suman DS, Wang Y, Klinger K, Faraji A, Gaugler R. Effectiveness of autodissemination stations containing pyriproxyfen in reducing immature *Aedes albopictus* populations. Parasites & Vectors. 2017; 10:139.

71. Suman DS, Farajollahi A, Healy S, Williams GM, Wang Y, Schoeler G, et al. Point-source and area-wide field studies of pyriproxyfen autodissemination against urban container-inhabiting mosquitoes. Acta Trop. 2014; 135: 96-103.
72. Lloyd AM, Farooq M, Estep AS, Xue RD, Kline DL. Evaluation of pyriproxyfen dissemination via *Aedes albopictus* from a point-source larvicide application in Northeast Florida. *J Am Mosq Control Assoc.* 2017; 33(2): 151-155.

73. Swale DR, Li Z, Kraft JZ, Healy K, Liu M, David CM, et al. Development of an autodissemination strategy for the deployment of novel control agents targeting the common malaria mosquito, *Anopheles quadrimaculatus* say (Diptera: Culicidae). *PLoS Negl Trop Dis.* 2018; 12(4): e0006259.

74. Iyaloop DP, Elahee KB, Bheecarry A, Lees RS. Guidelines to site selection for population surveillance and mosquito control trials: a case study from Mauritius. *Acta Trop.* 2014; 132S: S140-S149.

75. Arbaoui AA, Chua TH. Bacteria as a source of oviposition attractant for *Aedes aegypti* mosquitoes. *Trop Biomed.* 2014; 31(1): 134-142.

76. Liu H, Dixon D, Bibbs CS, Xue RD. Autocidal gravid ovitrap incorporation with attractants for control of gravid and host-seeking *Aedes aegypti* (Diptera: Culicidae). *J Med Entomol.* 2018; 56(2): 576-578.

77. Jerry DCT, Mohammed T, Mohammed A. Yeast-generated Co2: A convenient source of carbon dioxide for mosquito trapping using the BG-Sentinel® traps. *Asian Pacific Journal of Trop Biomed.* 2017; 7; 896-900.
Legends to figures

**Fig. 1** Cross section and schematic image of the MHS and MHAQ solution bottle

**Fig. 2** The oviposition bioassay design. The purple curved arrows indicate the changes in direction of the oviposition cup positions in the cages. **a** Four oviposition sites with: (i) Mosquito home aqua (MHAQ), (ii) Hay Infusion (HI), (iii) Tap Water a (TW a) and (iv) Tap Water b (TW b). **b** Four oviposition contained (i) MHAQ, (ii) TW a, (iii) TW b and (iv) TW c. **c** Four oviposition contained (i) MHAQ a, (ii) MHAQ b, (iii) MHAQ c and TW

**Fig. 3** *Aedes aegypti* as transportation for MHAQ transfer: Emergence inhibition over the MHAQ different concentrations for *Ae. aegypti* in untreated water. The red dashed line shows the threshold value of 80% above which the insecticide is considered effective

**Fig. 4** Response of gravid female *Aedes aegypti* when given a choice to oviposit in four cups containing MHAQ at different concentrations with water. **a** Oviposition sites: (i) MHAQ, (ii) HI, (iii) TW a and (iv) TW b. **b** Oviposition sites: (i) MHAQ, (ii) TW a, (iii) TW b, and (iv) TW c. **c** Oviposition sites: (i) MHAQ a, MHAQ b, MHAQ c, and TW. Means sharing the same letter are not statistically different from one another (*p* > 0.05)

**Fig. 5** Residual effects of MHAQ at different concentrations on *Ae. aegypti* larvae. The values at each point (every 10 days) represent the mean pupal mortality ± SE (%). The MHAQ concentrations with significant differences are represented by different superscript letters (repeated measures ANOVA; *p* < 0.001 by Tukey post-hoc test)
Fig. 6 The mean number of eggs (± SE) collected in the ovitraps and MHSs during intervention period at small-scale field trials (n = 48). Significant differences are indicated by asterisks (Repeated Measure - ANOVA, *p < 0.05, **p < 0.01, *** p < 0.001, ns = not significant)

Fig. 7 The mean percentage (±SE) of pupal mortality in water samples collected from the MHSs and ovitraps using larval bioassay in the treatment and control areas throughout 36 weeks during 2017-2018.
**Table 1** Mean number (± SE) of eggs laid in treated and untreated ovitraps with different ranges of MHAQ concentration and number of mosquitoes.

| No. of Mosquitoes | Concentration (ppm) | Mean no. of eggs laid | P-value |
|-------------------|----------------------|-----------------------|---------|
|                   |                      | Treated               | Untreated |         |
| One               | 0.5                  | 16.00 ± 2.31<sup>a</sup> | 9.00 ± 2.00<sup>a</sup> | 1.00    |
|                   | 1.0                  | 6.33 ± 2.19<sup>a</sup> | 5.51 ± 3.18<sup>a</sup> | 0.38    |
|                   | 20                   | 8.67 ± 2.03<sup>a</sup> | 9.00 ± 2.65<sup>a</sup> | 0.61    |
|                   | 40                   | 12.67 ± 2.85<sup>a</sup> | 7.00 ± 3.61<sup>a</sup> | 0.64    |
| Three             | 0.5                  | 57.00 ± 11.14<sup>a</sup> | 47.00 ± 10.44<sup>a</sup> | 0.78    |
|                   | 1.0                  | 42.67 ± 10.33<sup>a</sup> | 16.67 ± 5.24<sup>a</sup> | 0.28    |
|                   | 20                   | 31.33 ± 7.75<sup>a</sup> | 23.00 ± 4.16<sup>a</sup> | 0.21    |
|                   | 40                   | 48.00 ± 11.72<sup>a</sup> | 18.33 ± 6.69<sup>a</sup> | 0.38    |
| Five              | 0.5                  | 67.67 ± 32.35<sup>a</sup> | 40.33 ± 7.13<sup>a</sup> | 0.12    |
|                   | 1.0                  | 114.33 ± 32.85<sup>a</sup> | 62.67 ± 24.91<sup>a</sup> | 0.04    |
|                   | 20                   | 66.67 ± 16.83<sup>a</sup> | 47.67 ± 19.92<sup>a</sup> | 0.93    |
|                   | 40                   | 78.00 ± 21.20<sup>a</sup> | 51.33 ± 8.65<sup>a</sup> | 0.11    |

*Mean values in the same row denoted with different letters are significantly different (p < 0.001)*
Table 2. Effects of MHAQ on fecundity, fertility, and wing length on *Aedes aegypti* mosquitoes.

| Parameter                  | Treated       | Control       |
|----------------------------|---------------|---------------|
| **Fecundity**              |               |               |
| No. of eggs laid           | 53.70 ± 13.64<sup>a</sup> | 112.80 ± 20.82<sup>b</sup> |
| ER (%)                     | 52.40         |               |
| **Fertility**              |               |               |
| No. of hatching eggs       | 70.67 ± 3.64<sup>a</sup> | 92.80 ± 1.72<sup>b</sup> |
| ER (%)                     | 23.46         |               |
| **Wing length (mm)**       |               |               |
| Female                     | 2.23 ± 0.06<sup>a</sup> | 2.63 ± 0.05<sup>b</sup> |
| Male                       | 2.09 ± 0.03<sup>a</sup> | 2.19 ± 0.04<sup>b</sup> |

*Groups in the same row that shows a different letter are significantly different (p < 0.05)
An evaluation of a Mosquito home system for controlling Aedes aegypti
Table 1 Mean number (± SE) of eggs laid in treated and untreated ovitraps with different ranges of MHAQ concentration and number of mosquitoes.

| No. of Mosquitoes | Concentration (ppm) | Mean no. of eggs laid | P-value |
|-------------------|----------------------|-----------------------|---------|
|                   |                      | Treated               | Untreated |       |
| One               | 0.5                  | 16.00 ± 2.31<sup>a</sup> | 9.00 ± 2.00<sup>a</sup> | 1.00   |
|                   | 1.0                  | 6.33 ± 2.19<sup>a</sup> | 5.51 ± 3.18<sup>a</sup> | 0.38   |
|                   | 20                   | 8.67 ± 2.03<sup>a</sup> | 9.00 ± 2.65<sup>a</sup> | 0.61   |
|                   | 40                   | 12.67 ± 2.85<sup>a</sup> | 7.00 ± 3.61<sup>a</sup> | 0.64   |
| Three             | 0.5                  | 57.00 ± 11.14<sup>a</sup> | 47.00 ± 10.44<sup>a</sup> | 0.78   |
|                   | 1.0                  | 42.67 ± 10.33<sup>a</sup> | 16.67 ± 5.24<sup>a</sup> | 0.28   |
|                   | 20                   | 31.33 ± 7.75<sup>a</sup> | 23.00 ± 4.16<sup>a</sup> | 0.21   |
|                   | 40                   | 48.00 ± 11.72<sup>a</sup> | 18.33 ± 6.69<sup>a</sup> | 0.38   |
|                   | 0.5                  | 67.67 ± 32.35<sup>a</sup> | 40.33 ± 7.13<sup>a</sup> | 0.12   |
| Five              | 1.0                  | 114.33 ± 32.85<sup>a</sup> | 62.67 ± 24.91<sup>a</sup> | 0.04   |
|                   | 20                   | 66.67 ± 16.83<sup>a</sup> | 47.67 ± 19.92<sup>a</sup> | 0.93   |
|                   | 40                   | 78.00 ± 21.20<sup>a</sup> | 51.33 ± 8.65<sup>a</sup> | 0.11   |

*Mean values in the same row denoted with different letters are significantly different (p < 0.001)
**Table 2.** Effects of MHAQ on fecundity, fertility, and wing length on *Aedes aegypti* mosquitoes.

| Parameter          | Treated         | Control         |
|--------------------|-----------------|-----------------|
| **Fecundity**      |                 |                 |
| No. of eggs laid   | $53.70 \pm 13.64^a$ | $112.80 \pm 20.82^b$ |
| ER (%)             | 52.40           |                 |
| **Fertility**      |                 |                 |
| No. of hatching eggs | $70.67 \pm 3.64^a$ | $92.80 \pm 1.72^b$ |
| ER (%)             | 23.46           |                 |
| **Wing length (mm)** |               |                 |
| Female             | $2.23 \pm 0.06^a$ | $2.63 \pm 0.05^b$ |
| Male               | $2.09 \pm 0.03^a$ | $2.19 \pm 0.04^b$ |

*Groups in the same row that shows a different letter are significantly different (p < 0.05)*
Figure 1

An evaluation of a Mosquito home system for controlling Aedes aegypti
An evaluation of a Mosquito home system for controlling Aedes aegypti
An evaluation of a Mosquito home system for controlling Aedes aegypti
An evaluation of a Mosquito home system for controlling Aedes aegypti

a. bioassay 1

Mean number of eggs

| Oviposition Site | MHAQ | HI | TW a | TW b |
|------------------|------|----|------|------|
| Mean number      | 450  | 350| 250  | 200  |

b. bioassay 2

Mean number of eggs

| Oviposition Site | MHAQ | TW a | TW b | TW c |
|------------------|------|------|------|------|
| Mean number      | 500  | 400  | 300  | 200  |

C. bioassay 3

Mean number of eggs

| Oviposition Site | MHAQ a | MHAQ b | MHAQ c | TW    |
|------------------|--------|--------|--------|-------|
| Mean number      | 500    | 400    | 300    | 200   |
Figure 5

An evaluation of a Mosquito home system for controlling Aedes aegypti

![Graph showing inhibition emergence over days for different concentrations of the system.](Fig. 5.tiff)
An evaluation of a Mosquito home system for controlling *Aedes aegypti*
An evaluation of a Mosquito home system for controlling Aedes aegypti
An evaluation of a Mosquito home system for controlling Aedes aegypti

Click here to access/download
Supplementary Material
Journal Response_MMinor Revision.docx